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ABSTRACT
OBJECTIVE: The objective of the systematic review is to determine whether or not chronic use
of Bacopa monnieri is an effective treatment to improve memory performance in healthy and
aging adults.
STUDY DESIGN: Review of three English language primary studies published in 2006, 2008
and 2008.
DATA SOURCES: Randomized, double-blind, placebo-controlled trials comparing chronic use
of Bacopa monnieri extract to placebo were found using Ovid MEDLINE, PubMed and
Cochrane databases.
OUTCOMES MEASURED: Ability to recall newly learned information evaluated using the
Cognitive Drug Research (CDR) cognitive assessment system, the Rey Auditory Verbal
Learning Test (AVLT) and the Wechsler Memory Scale.
RESULTS: All three RCT’s included in this review found significant improvement versus
placebo in the realm of recalling newly learned information, specifically in spatial working
memory, paired associated learning and delayed word recall memory tests.
CONCLUSIONS: The results of the RCT’s reviewed demonstrate that chronic use of B monnieri
extract has the potential to significantly improve cognitive function, namely the ability to recall
newly learned information, in healthy as well as the elderly with age-related cognitive
impairment.
KEY WORDS: Bacopa monnieri, Brahmi, cognitive, memory
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INTRODUCTION
Memory, or the ability to recall information, is a common subject of complaint in
healthcare as evidenced by the ADHD patient who cannot remember what he or she just read or
by the aging patient who complains of an increasing inability to think of the right word to
describe something. Even in the perfectly healthy individual memory has its limit. The desire to
improve one’s memory is near universal, and a recent study at the University of Sterling found
that people with better working memory tend to be happier and more successful.1 While
memory is a multifactorial and not fully understood process, the weakening of the memory can
be disabling and costly to patients. Conversely, the improvement of memory can lead to more
effective living.
As many as one-third of adults will experience mild cognitive decline as they age4, and
with an aging baby-boomer demographic beginning to enter their golden years, a desire for
treatment and improvement in memory may increase in demand. While drugs such as Aricept
and Namenda are being effectively used for Alzheimer’s related cognitive decline, no
pharmaceutical drugs or supplements are FDA approved to improve normal or age-related
memory decline. Concurrently, there is a trend towards health consumers turning to
complementary and alterative medicine (CAM) in the United States, with approximately $34
billion spend on it in 20077. A recent report revealed Americans spent $107 million dollars on
gingko biloba in hopes to improving memory.2 As patients in a primary care setting increasingly
inquire about supplements and herbs such as ginkgo--and indeed may be taking them without the
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providers’ knowledge-- it becomes important to know the evidence in order to educate patients in
making informed decisions with their health.
Traditionally conservative methods such as low fat diets, regular exercise, adequate
intake of fish, tight glucose control and adequate sleep of all been posited to stave off or improve
memory decline.4 While the exact workings of memory and its decline are unknown, researchers
have pointed to declining levels of neurotransmitters such as acetylcholine, serotonin and DHEA,
a decrease in neurons and frequency of nerve impulses, oxidative damage to neurons (especially
in the hippocampus), chronic inflammation and decreased blood flow to the brain, among others
as responsible mechanisms.4 Many supplements ranging from B-vitamins to coffee to “smart
drugs” like piracetam are marketed to improve cognitive function and enhance memory. As
interest and research grows in this field, efforts must be made to evaluate the evidence to support
their use. To illustrate the importance of evidence behind these therapies, a recent, federally
funded study to evaluate gingko biloba in preventing age related cognitive decline was published
in JAMA in 2009 and showed no difference versus placebo.3
Bacopa monnieiri (Brahmi) is another herb—a leaf extract of water hyssop, a popular
aquarium plant--has garnered recent attention for its potential in improving memory. It is being
sold today in health food stores such as Whole Foods an GNC. Traditionally it has been used as
far back as the 6th century in Ayurvedic medicine for enhancing memory, analgesia and treating
epilepsy.5 Today it is being used in alternative medicine and supplement for cognition, memory,
anxiety, IBS and epilepsy. The exact mechanism of action is unknown, but it is thought that
saponins from B monnieri are responsible for its positive effects, hypothetically by upregulation
of cholinergic regulation, GABA modulation with anxiolytic effects, antioxidant effects in the
prefrontal cortex, striatum and hippocampus (as evidenced in chronic use in mice models),
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altered protein synthesis in the brain, 5-HT agonism and modulation of brain stress hormone.
8,9,10

Early trials have not shown any significant benefit from B monnieiri use in the acute setting,

but small and preliminary studies have shown some promise of benefit in the arena of memory
with chronic use (90 days) of B monnieri.
OBJECTIVE
The goal of this review is to determine if chronic use (of at least 3 months) of a
standardized extract of B monnieri is an effective treatment to improve memory performance in
healthy and aging adults.

METHODS
A search to locate RTC’s that evaluated extract of B monnieiri on memory performance
in adults was performed. The different interventions used were 300mg standardized extract/day
taken for 12 weeks; 150mg of specialized extract for twice a day for 90 days; and 125mg of
standardized extract taken twice a day for 12 weeks followed by four weeks of placebo. The
common denominator of these studies is administration of at least 250mg per day for at least 12
weeks (84 days). All of these interventions were compared versus placebo. Outcomes included
working memory, word recall, spatial memory, anxiety and visual information processing. The
studies included in this review were all randomized, double-blind placebo controlled studies.
Key words used for the search were “Brahmi” (the Indian name for B monnieiri), “B
monnieiri”, “cognitive” and “memory”. All three studies were published and written in the
English language. The Cochrane Database of Systematic Reviews, PubMed and Ovid
MEDLINE—“2000 to present” were used to locate the studies published in 2006, 2008 and 2008
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respectively. Criteria for selection were those published in 2000 or later, included human beings
and were in the English language, dealt with POEMS and were RCT’s not previously used for
SRs or MAs. The researchers of the studies were from the Brain Sciences Institute from
Swinburne University, KG Medical University researchers in India, and the National College of
Natural Medicine in conjunction with OHSU in Portland, Oregon.

OUTCOMES MEASURED
The outcomes evaluated in the respective studies were POEMS such as the ability to
recall new information, change in anxiety level, attention, working memory, spacial working
memory and the ability to recall information after delay or with distraction. To evaluate these
POEMS, the Wechsler Memory Scale, Cognitive Drug Research cognitive assessment system
(CDR) and Rey Auditory-Verbal Learning Test (AVLT) were used. All three of the studies used
very similar interventions of at least 250mg of a standardized or “specialized” B monnieiri
extract that included at least 50% concentration of bacosides A and B versus placebo. They were
all conducted over chronic courses defined as at least 12 weeks. Two of the studies used healthy
adult populations while the other study used a population of adults with complaints of insidious
age-related cognitive impairments. The major characteristics of the studies under review are
organized in Table 1.
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Table of demographics of included studies: Table 1
CHARACTERISTICS OF STUDIES INCLUDED IN THE SYSTEMATIC REVIEW OF
THE EFFICACY OF BACOPA MONNIERI VERSUS PLACEBO IN IMPROVING
MEMORY PERFORMANCE
Study
Type
#Pts
Age/
Inclusion
Exclusion
W/D Interventions
Yrs
Criteria
Criteria
Calabrese, Double2008 (1)
blind,
placebo
controlled
RCT

54

65+

Living
independently,
without signs
of dementia

Stough,
2008 (2)

Doubleblind,
placebo
controlled
RCT

107

1860

Healthy

Raghav,
2006 (3)

Doubleblind,
placebo
controlled
RCT

40

55+

Complaints of
insidiousonset memory
impairment.
<6 on
Wechsler
Memory Scale

No meds other 6
than ASA,
NSAIDs,
vitamins,
stable doses of
thyroid med,
HRT, antiHTN or
cholesterol
drugs
Hx of
35
dementia,
psychiatric or
neurological
disorders
endocrine
disorder,
chronic illness
or infection,
pregnant or
lactating,
Taking anticoagulators,
ACE
inhibitors, antiParkinson’s or
any other
cognition
enhancing
drug, cigarette
smoking.
Evidence of
5
dementia or
psychiatric
disorder.
> 24 on
MMSE

Standardized
B. monnieri
extract of
300 mg/day
taken orally
for 12 weeks

Specialized
extract of B.
monnieri
300mg/day
taken orally
or 90 days

Standardized
B. monnieri
extract
125mg BID
for 12 weeks
followed by
4 weeks of
placebo
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RESULTS
Table 2 displays a summary of results from a study conducted by Calabrese et al. in
2008. For the purpose of this analysis, results from the AVLT, or the Rey Auditory-Visual
Learning Test, were chosen from the battery of measurements only if they directly related to
memory. The AVLT measures short-term auditory-verbal memory among other facets of the
memory such retention, retrieval accuracy and the like.8 The Blessed Orientation-MemoryConcentration (BOMC) and Wide Range Achievement Test (WRAT) were administered at
baseline to participants and along with gender were analyzed using ANCOVA and ANOVA to
determine if covariate were effecting significance. F values were all < 1 signifying that
covariates did not differ between groups or gender.8 The ability of the bacopa group to recall
words after delay had a significant increase (p 0.03) whereas placebo did not. The control group
recall scores did not change significantly over 12 weeks, while the experimental arm scores
increased by 1 word over 12 weeks. Significance was not seen until the 12th week interval
testing.8

Table 2. Comparing AVLT Delayed Recall Scores Over Time in B monnieiri Versus Placebo8
Calabrese et al., 2008
Means for Cognitive Measures at Baseline, 6 weeks and 12 weeks in using AVLT Delayed
Recall (# of words)
η
Variables
Group
Baseline +6 weeks +12 weeks
F
df
p
M (SD) M (SD)
M (SD)
AVLT
Placebo 6.8 (3.6) 6.6 (3.9)
6.9 (4.2)
<1
Delayed Recall
7.6 (3.9)
5.4
1,21 0.03
0.20
(# of words) Bacopa 6.4 (3.1) 6.6 (3.6)
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The results from a 2008 study conducted by Stough et al. are presented in Table 3 and
Table 4. The main evaluation in this experiment used the CDR computerized assessment test.
The CDR assesses speed of attention, speed of memory, accuracy of attention, secondary and
working memory via a variety of tests9. For the purpose of this analysis, only measures
pertaining to secondary and working memory were examined. ANOVA conduction revealed a
significance within the class of “Working Memory” tests F(1,53) = 4.70, p = 0.035 (Table 4) and
specifically within in this class, “Spatial Working Memory” improved significantly F(1,54) =
3.98, p = 0.051 (Table 3).9 It is important to note that in the class of “Secondary Memory” there
was no significant difference between groups. Note that secondary memory is also referred to as
long-term memory in psychological parlance. In the specific tests of numeric-working memory,
delayed-word recall, word-recognition recall and delayed-picture recall, no significant difference
between placebo and the experimental arm was detected.

Table 3. Effect of B monnieri treatment on the CDR measure of spatial working memory9
C. Stough et al, 2008 study
Measure
Spatial Working
Memory (%
Correct)
Numeric Working
Memory (%)
correct
Delayed Word
Recall (%)

Tx group
Placebo

N
28

Mean
95.67

SD Baseline
6.91

Mean
97.97

SD Post Tx
2.53

Bacopa

33

91.40

9.99

96.84*

5.91

Placebo

28

92.94

6.34

91.89

8.26

Bacopa

33

93.70

6.15

93.80

5.22

Placebo

29

28.74

11.90

34.37

13.37

Bacopa

31

31.61

14.40

34.58

14.46

Word Recognition
Recall (%)

Placebo

29

81.72

11.43

84.14

8.48

Bacopa

33

83.84

8.50

85.15

9.43

Delayed Picture
Recognition (%
correct)

Placebo

29

84.40

7.75

86.90

9.18

Bacopa

33

86.29

8.73

86.82

10.94
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Table 4. Baseline and Post-treatment scores for the “working memory” CDR measure9
C. Stough et al, 2008 study
CDR factor
Working
Memory
Secondary
Memory
* p < 0.05

Treatment
Bacopa
Placebo
Bacopa
Placebo

M (baseline)
185.11
188.71
246.64
236.93

SD (baseline)
13.16
9.50
33.73
34.75

M (post-tx)
190.64 *
189.85
254.66
251.49

SD (post-tx)
9.39
9.08
39.36
34.53

Table 5 shows the results from a 2006 study conducted by Raghav et al., a study that
used participants who have age-related cognitive impairment in contrast to the other two studies
in this review. The Wechsler Memory Scale was used to evaluate memory function. Subtests of
the WMS were used and are represented in Table 5. At 12 weeks, paired t-test analysis showed
significant improvement in the Bacopa arm in the areas of mental control, logical memory,
paired associate learning and total memory score (p < 0.01) as well as in digit forward (p <
0.05).10 No significant differences were seen in digit backward testing and visual reproduction
measures. Moreover, no memory loss nor loss of gains was seen from week 12 to week 16 in the
Bacopa arm when placebo was used in both groups for the last four weeks. When improvement
of > 21% is set to define what constitutes a considerable gain, 55% of the Bacopa subjects
improved considerably as opposed to none in the placebo group.10 With this dichotomous
determination made, NNT would be 2 patients.
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Table 5. Comparison of Wechsler Memory Scale scores of B monnieri versus placebo groups at
0, 4, 8, 12 and 16 weeks10
Variables
0 week
Mental Control
Bacopa
7.4 +/- 0.9
Placebo
7.7 +/- 0.6
‘t’
Logical Memory
Bacopa
4.3 +/- 1.1
Placebo
4.8 +/- 1.1
‘t’
Paired Associate Learning
Bacopa
13.9 +/- 3.6
Placebo
12.7 +/- 1.4
‘t’
Digit Forward
Bacopa
6.3+/- 0.5
Placebo
6.8 +/- 0.7
‘t’
Digit Backward
Bacopa
5.5+/- 0.3
Placebo
5.7 +/- 0.7
‘t’
Visual Reproduction
Bacopa
11.7 +/- 1.6
Placebo
12.0 +/- 1.9
‘t’
Total Memory Score
Bacopa
57.4+/- 4.4
Placebo
57.5 +/- 3.1
‘t’
* p < 0.05 ** p< 0.01

Raghav et al, 2006
4 week
8 week

12 week

16 week

7.8 +/- 0.7
7.7 +/- 0.6
1.94

8.2 +/- 0.9
8.0 +/- 0.4
2.06

8.6 +/- 0.6**
8.0 +/- 0.4
3.53

8.6 +/- 0.6
8.0 +/- 0.4

5.9 +/- 1.2**
5.5 +/- 1.3
2.58

7.4 +/- 1.2**
6.4 +/- 1.8*
2.47

8.7 +/- 2.1 **
6.7 +/- 1.6
3.48

8.8+/- 2.1
6.7 +/- 1.4

14.6 +/-3.3
13.2 +/- 1.2
1.26

16.8 +/-2.4 ** 18.1 +/- 2.3** 18.2 +/- 2.1
13.7 +/- 2.1* 14.5 +/ -1.8
14.5 +/ -1.7
1.9
2.48

6.8 +/- 0.7
6.7 +/- 0.7
1.4

6.6 +/- 0.7
6.8 +/- 0.6
0.55

7.0 +/- 0.7*
6.8 +/- 0.7
0.96

7.0+/- 0.4
6.8 +/- 0.6

5.2 +/- 0.4
5.7 +/- 0.8

5.2 +/- 0.5
5.6 +/- 0.6

5.2 +/- 0.4
5.7 +/- 0.6

5.9 +/- 0.8
5.7 +/- 0.6

11.5 +/- 1.7
12.1 +/- 1.8

11.6 +/- 1.6
12.0 +/- 2.1

11.7 +/- 1.7
12.1 +/- 2.2

11.7 +/- 1.7
12.1 +/- 2.1

60.8 +/- 4.7*
59.1 +/- 3.4
2.87

66.9 +/- 4.7** 70.2 +/- 4.8** 70.6 +/- 4.0
63.3 +/- 4.9
64. 6 +/- 4.8
64.4 +/- 4.9
10.7
4.98

As mentioned previously, one study did use subjects with insidious age-related cognitive
impairment (Raghav et al.) while the others used healthy participants. Exclusion criteria were
similar and only one study reported compliance (Calabrese et al.), which was high with an
average of 3.9 pills missed over 12 weeks with no significant difference between control and
interventional arm.8,10 Adverse advents, although not under examination in this review, are still
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worth mentioning as it might affect compliance, but in all three studies no significant difference
between placebo and Bacopa intervention.8,9,10
DISCUSSION
Each study showed some significant improvement in a facet of memory with the most
impressive gains reported in the Raghav et al. study in which participants were suffering from
age-related cognitive impairment with a Wechsler score < 6.10 It is not understood why gains
would be made in one area of memory and not others, but what the statistics do bear out is that
working or “short-term memory,” to put it simply, is significantly improved in the interventional
group in all 3 studies. Certain subtests in the studies such “visual reproduction” (Raghav study)
and “numeric working memory” (Stough study) show no difference between groups. Given the
complexity of the human brain and memory, it is difficult to say why this would be. An obvious
limitation of all of the studies in this review is small sample size that confers weak statistical
power.
With respect to clinical use of this herb, the Natural Standard reports that palpitations, dry
mouth, nausea and fatigue have been reported with use.5 Based on animal studies, caution
should be used in patients taking drugs metabolized by the cytochrome P450 enzyme, in patients
receiving treatment for thyroid disorders as it may increase levels and patients taking CCBs or
sedatives to potentiation due to potential additive effects.5
CONCLUSION
Yes, B monnieiri has the potential to be an effective treatment to improve memory
performance in both the healthy and aging adults, including those suffering from age-related
memory impairment. It is recommended that large scale, long duration studies are conducted to
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confirm and strengthen the evidence for using this herb. Moreover, long-term studies might be
explored for its potential to play a role in protecting or delaying age-related memory decline or
delay Alzheimer’s disease onset and/or progression. It is interesting to note that cognitive gains
made in the Raghav study that involved patients with insidious age-related cognitive impairment
were maintained even after discontinuing the intervention. This is a promising clinical POEM
that would benefit patients if larger studies bear out similar significant evidence in the future.
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